Sustainability Report

Overview

The report highlights FDA approval of iDose TR after more than 15 years of research and development, expanded patient access programs, and a two-site distribution model that eliminated 6.4 million air miles. It reports 913 employees, $315M in 2023 net sales, 58% renewable energy, and Scope 1 and Scope 2 emissions of 575.4 and 2,159.4, respectively. The report also describes Board oversight of sustainability and reports zero employee and contractor fatalities.

Document

Report type: Sustainability Report
Class: Dedicated
Scope: Full report
Fiscal year: 2023
Period: 1 January 2023 – 31 December 2023
Language: English
Pages
File size
Restatement: Disclosed

Reporting standards, commitments and assurance details are available with a free account.

Standards

GRI
SASB
TCFD
ISSB
ESRS
Integrated Reporting Framework
GHG Protocol
EU Taxonomy
CDP
Other

Ratings

GRI level

Materiality

Assessment
Basis

Assurance

Statement included

Data Services

Turn sustainability reports into a dataset built for your research.

From bulk PDFs to structured indicators and machine-readable documents.

View services